MedPath
HSA Approval

BLOKBIS TABLET 2.5MG

SIN15804P

BLOKBIS TABLET 2.5MG

BLOKBIS TABLET 2.5MG

September 12, 2019

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Licence HolderTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

C07AB07

bisoprolol

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Chanelle Medical Unlimited Company

Active Ingredients

Bisoprolol Fumarate

2.5 mg

Bisoprolol

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

BLOKBIS TABLET 2.5MG - HSA Approval | MedPath